Targeting PTBP3‐Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis

Targeting PTBP3‐Mediated Alternative Splicing of COX11 Induces Cuproptosis for Inhibiting Gastric Cancer Peritoneal Metastasis

Abstract Numerous aberrant splicing events are implicated in tumor progression, yet comprehensive reports on splicing factors and events associated with peritoneal metastasis in gastric cancer (GCPM) are lacking. In this study, PTBP3 is found to be significantly overexpressed in peritoneal metastati...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yajing Zhou, Chao Dong, Xiaochun Shen, Pengbo Wang, Tao Chen, Weikang Li, Xiaotong Sun, Peiyuan Li, Chengxiang Xu, Kaipeng Duan, Dongbao Li, Jin Zhou
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	Advanced Science
Subjects:	alternative splicing antisense oligonucleotide drugs cuproptosis gastric cancer peritoneal metastasis patient‐derived organoids‐based xenograft
Online Access:	https://doi.org/10.1002/advs.202415983
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations
by: Pushkar Malakar, et al.
Published: (2024-12-01)

Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides
by: Anthony J Hinrich, et al.
Published: (2016-02-01)

RNA structure in alternative splicing regulation: from mechanism to therapy
by: Bao Nengcheng, et al.
Published: (2024-07-01)

The RNA revolution in medicine: from gene regulation to clinical therapeutics
by: Jiwon Jeong, et al.
Published: (2025-12-01)

Antisense oligonucleotide therapy for patients with Friedreich’s ataxia carrying the c.165+5G>C splicing mutation
by: Pouiré Yameogo, et al.
Published: (2025-09-01)

Splicing correction by peptide-conjugated morpholinos as a novel treatment for late-onset Pompe disease
by: Ryan A. Oliver, et al.
Published: (2025-06-01)

Clinically relevant pseudoexons of the GALNS gene and their antisense-based correction
by: Igor Bychkov, et al.
Published: (2025-05-01)

Dysregulation and Therapeutic Targeting of RNA Splicing Variants in Cancer
by: Doaa Rabaya, et al.
Published: (2024-09-01)

Delivery is key: lessons learnt from developing splice‐switching antisense therapies
by: Caroline Godfrey, et al.
Published: (2017-03-01)

Locked nucleic acid-modified antisense oligonucleotides attenuate scar hyperplasia through targeted inhibition of CTGF
by: Jinhe Li, et al.
Published: (2025-08-01)

In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01)

LIPID METABOLISM CORRECTION BY ANTISENSE TECHNOLOGY
by: O. I. Afanasieva, et al.
Published: (2015-09-01)

Effective inhibition of dengue virus replication using 3′UTR-targeted Vivo-Morpholinos
by: Mengwei Niu, et al.
Published: (2024-11-01)

Discovery and characterization of stereodefined PMO-gapmers targeting tau
by: Kunihiko Kanatsu, et al.
Published: (2025-03-01)

Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01)

Design and screening of novel endosomal escape compounds that enhance functional delivery of oligonucleotides in vitro
by: H. Yesid Estupiñán, et al.
Published: (2025-06-01)

HnRNPM modulates alternative splicing in germ cells by recruiting PTBP1
by: Peng Lv, et al.
Published: (2025-01-01)

RNA splicing variants of the novel long non-coding RNA, CyKILR, possess divergent biological functions in non-small cell lung cancer
by: Xiujie Xie, et al.
Published: (2025-03-01)

Tumor exosomal circPTBP3 drives gastric cancer peritoneal metastasis via mesothelial-mesenchymal transition
by: Chao Dong, et al.
Published: (2025-06-01)

Employing splice-switching oligonucleotides and AAVrh74.U7 snRNA to target insulin receptor splicing and cancer hallmarks in osteosarcoma
by: Safiya Khurshid, et al.
Published: (2024-12-01)

Technique of Overlap Extension by Polymerase Chain Reaction for Splicing Cauliflower Mosaic Virus (CaMV) 35S Promoter and DhPEX11-Like
by: Silvi Ikawati, et al.
Published: (2015-06-01)

Multispanning membrane protein SIDT2 increases knockdown activity of gapmer antisense oligonucleotides
by: Kohshi Kusumoto, et al.
Published: (2025-01-01)

Impact on efficacy of target reduction of two FDA-approved ASO drugs by intracellular glucose levels in in vitro cell models
by: Le Tra Giang Nguyen, et al.
Published: (2025-03-01)

Integrating datasets to dissect NFYC-AS1 RNA- and transcription-dependent functions: comparative transcriptome profiling of knockdown strategiesGene Expression Omnibus GEO
by: Giulia Pagani, et al.
Published: (2025-06-01)

PTBP1 Regulates DNMT3B Alternative Splicing by Interacting With RALY to Enhance the Radioresistance of Prostate Cancer
by: Haixia He, et al.
Published: (2024-11-01)

LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
by: U. Julius, et al.
Published: (2018-09-01)

Therapeutics in paediatric genetic diseases: current and future landscape
by: Ai Ling Koh, et al.
Published: (2023-01-01)

Pwp1 inhibition impairs the development and early lineage commitment of mouse preimplantation embryos
by: Takuto YAMAMOTO, et al.
Published: (2025-05-01)

Evaluation of an Antisense Oligonucleotide Targeting CAG Repeats: A Patient-Customized Therapy Study for Huntington’s Disease
by: Sergio Adrian Ocampo-Ortega, et al.
Published: (2024-12-01)

Personalized allele-specific antisense oligonucleotides for GNAO1-neurodevelopmental disorder
by: Inna Shomer, et al.
Published: (2025-03-01)

LincRNA-ASAO promotes dental pulp repair through interacting with PTBP1 to increase ALPL alternative splicing
by: Fuchun Fang, et al.
Published: (2025-03-01)

Proximal spinal muscular atrophy 5q in the Republic of North Ossetia – Alania: population-genetic features, diagnostic problems and treatment prospects
by: I. S. Tebieva, et al.
Published: (2022-06-01)

STXBP1 Syndrome: Biotechnological Advances, Challenges, and Perspectives in Gene Therapy, Experimental Models, and Translational Research
by: Silvestre Ruano-Rodríguez, et al.
Published: (2025-02-01)

Efficacy and safety of Viltepso® in Duchenne muscular dystrophy: review of clinical studies
by: V. M. Suslov, et al.
Published: (2024-11-01)

ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS
by: O. I. Afanasieva, et al.
Published: (2018-09-01)

Anti-TNF-α antisense-oligonucleotide-conjugated PLG nanoparticles protect transplanted islets
by: Elizabeth J. Bealer, et al.
Published: (2025-06-01)

ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses
by: Rebecca L. Wallings, et al.
Published: (2025-04-01)

Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy
by: Hüseyin Bahadır Şenol, et al.
Published: (2025-01-01)

Systematic analysis of genetic and phenotypic characteristics reveals antisense oligonucleotide therapy potential for one-third of neurodevelopmental disorders
by: Kim N. Wijnant, et al.
Published: (2025-05-01)

Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells
by: Rachele Rossi, et al.
Published: (2024-11-01)